Table IV.
Comparison between the absolute sCD36 concentrations from different studies.
| Controls | Cases | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Human sCD36 ELISA | Study | Country | Age, years | Sample | Details | Total, n | sCD36, ng/ml | Details | Total, n | sCD36, ng/ml | (Refs.) |
| Aviscera | Alkhatatbeh et al | Jordan | 53.8±9.7a | Plasma | Non-metabolic syndrome | 36 | 3.0 (1.6–4.8)b | Obese MetS | 41 | 3.0 (2.0–7.2)b | Current study |
| Bioscience, Santa Clara, CA USA | Ramos-Arellano et al | Mexico | 18–25c | Serum | Normal | 133 | 32.3 (16.8–102.4)b | Obese | 55 | 146.3 (76.7–694.7)b | (22) |
| Cusabio Biotech Wuhan, China | Wu et al | China | 18–25c | Plasma | Undergraduate university students | 464 | 74.1±39.8a | N/A | N/A | N/A | (23) |
| Himoto et al | Japan | 56.3±9.2a | Serum | Normal | 8 | 0.153±0.044a | Obese subjects with hepatitis C virus related chronic liver disease | 16 | 0.254±0.123a | (25) | |
| Garcia-Monzon et al | Spain | 47.9±13.8a | Serum | Normal | 85 | 0.173±0.137a | Non-alcoholic steatosis | 172 | 0.361±0.286a | (26) | |
| In house | Alkhatatbeh et al | Australia | 57±9a | Plasma | Normal lean subjects | 33 | 1,710 (0–6,079)b | Obese type 2 DM | 33 | 3,900 (1,670–7,642)b | (17) |
| Chmielewski et al | Sweden | 19–70c | Serum | No type 2 DM | 125 | 25.3 (19.9–42.5)b | Type 2 DM | 19 | 26.1 (21.2–40.1)b | (35) | |
| Wuhan EIAab Science Co., Ltd., | Krzystolik et al | Poland | 50.2 (47.3–53.9)b | Plasma | Males with early onset coronary artery disease | 75 | 10.7×109 (5.8×109-15.6×109)b | Females with early onset coronary artery disease | 25 | 17.5×109 (13.8×109-31.2×109)b | (24) |
Represents
a
mean ± standard deviation
b
median (interquartile range)
c
range. sCD36, soluble cluster of differentiation 36; MetS, metabolic syndrome; N/A, not available; DM, diabetes mellitus.